Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of EspeRare.

    Client Virtual Booth

    ESPERARE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    EspeRare
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Campus Biotech-EPFL Innovation Park Avenue Secheron 15 1202 Geneva
    Telephone
    Telephone
    +41 22 794 40 04
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://esperare.org/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/esperare-foundation
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pierre Fabre and the EspeRare Foundation Administer Investigational Treatment to First Patient in EDELIFE Clinical Trial for Rare Genetic Disease, XLHED

    Details:

    ER004 is a pioneering in-utero therapy designed to replace the function of endogenous Ectodysplasin A1 (EDA1), a protein key to the normal development of ectodermal structures in the foetus.


    Lead Product(s): ER004

    Therapeutic Area: Genetic Disease Product Name: ER004

    Highest Development Status: Phase IIProduct Type: Large molecule

    Recipient: Pierre Fabre

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pierre Fabre and The Espe Rare Foundation Start The EDELIFE Clinical Trial of A Prenatal Treatment for A Rare Genetic Disease, XLHED

    Details:

    The EDELIFE clinical trial will investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male foetuses who have been confirmed to have XLHED.


    Lead Product(s): ER004

    Therapeutic Area: Genetic Disease Product Name: ER004

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Pierre Fabre

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 15, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    The EspeRare Foundation and Pierre Fabre Join Forces to Develop and Market a Pioneering Treatment for XLHED

    Details:

    The Pierre Fabre group will be granted exclusive worldwide rights for the development, manufacturing and commercialization of ER-004. EspeRare and the Pierre Fabre Group will pool their respective expertise together in order to co-develop ER-004.


    Lead Product(s): ER-004

    Therapeutic Area: Genetic Disease Product Name: EDI200

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Pierre Fabre

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration December 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EspeRare Gets FDA Breakthrough Therapy Designation for ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia

    Details:

    The Breakthrough Therapy Designation was granted following the promising results from three XLHED subjects who were treated by Professor Holm Schneider with a course of ER-004 intra-amniotic injections during the third trimester of pregnancy.


    Lead Product(s): ER-004

    Therapeutic Area: Genetic Disease Product Name: ER-004

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 06, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search